Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $1.7 million.

  • UroGen Pharma's Gains from Investment Securities rose 2066.34% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 475.24%. This contributed to the annual value of $1.7 million for FY2024, which is 63.89% up from last year.
  • UroGen Pharma's Gains from Investment Securities amounted to $1.7 million in FY2024, which was up 63.89% from $1.0 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Gains from Investment Securities registered a high of $1.7 million during FY2024, and its lowest value of $400,600 during FY2020.
  • For the 3-year period, UroGen Pharma's Gains from Investment Securities averaged around $1.0 million, with its median value being $1.0 million (2023).
  • Per our database at Business Quant, UroGen Pharma's Gains from Investment Securities crashed by 58.08% in 2020 and then surged by 146.21% in 2023.
  • Over the past 5 years, UroGen Pharma's Gains from Investment Securities (Yearly) stood at $400,600 in 2020, then spiked by 48.03% to $593,000 in 2021, then crashed by 30.85% to $410,064 in 2022, then soared by 146.21% to $1.0 million in 2023, then skyrocketed by 63.89% to $1.7 million in 2024.